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HEALTH CARE UTILIZATION AND EXPENDITURES
ASSOCIATED WITH USE OF INSULIN GLARGINE
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2Boston University School of Public Health, Boston, MA, USA
OBJECTIVES: Long-acting insulin analogs, such as insulin
glargine, offer the promise of better glycemic control, reduced
risk of complications, and moderation of health care use and
costs in patients with diabetes. We studied initiation of insulin
glargine to evaluate its association with changes in clinical mea-
sures and subsequent health care utilization and expenditures.
METHODS: U.S. Veterans Health Administration (VA) patients
who initiated insulin glargine (N = 5,057) in 2001 or 2002 were
compared to a sample of diabetes patients continuing to receive
other insulin (N = 69,940), matched on month of prescription
(index date). Hemoglobin A1c (HgA1c), hypoglycemia rates, and
VA health care (inpatient and outpatient) in the 12 months after
a patient’s index date were compared. Utilization differences
were evaluated using Tobit regression and other differences using
linear and logistic regression, controlling for prior utilization,
demographics, co-morbidities, and diabetes severity. National
average utilization and pharmacy costs were used to estimate
value of VA expenditures. RESULTS: Insulin glargine initiators
were younger (59 vs. 65 years) than other insulin users with more
diabetes complications and more intensive medication manage-
ment. They had higher HgA1c (8.7% vs. 8.1%) and hypo-
glycemia rates (11.5% vs. 4.4%) prior to the index date, but
greater subsequent reductions (HgA1c: -0.50% vs.-0.24%;
hypoglycemia: -5.0% vs.-1.3%). Insulin glargine initiation was
associated with 2.4 (95% CI: 1.1–3.7) fewer inpatient days for
patients with any hospitalization (lower cost of $820 per initia-
tor). This more than offset the higher costs of more outpatient
encounters (1.6 (1.2–1.9) or $229 per initiator) and higher med-
ication costs ($347 ($337–$356) per initiator). CONCLUSION:
Insulin glargine use was associated with improvements in
glycemic control, hypoglycemia rates, and utilization expendi-
tures. We conclude that insulin glargine use may improve 
management of diabetes patients leading to reduced risk of 
complications and less time in hospital with no net increase in
cost.
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OBJECTIVES: This study compares the effect of two injectable
therapies, exenatide and insulin glargine, on quality of life mea-
surements in patients with Type-2 diabetes inadequately con-
trolled on oral antidiabetic medications. Previous research has
shown that increasing treatment complexity results in a negative
impact on patient reported outcomes. As exenatide and insulin
glargine are both adjunctive to pre-existing oral therapy in this
study, the impact on quality of life from adding an injectable
therapy is examined. Additionally, differences in quality of life
between the medications are examined. METHODS: Patients
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were randomized to either twice daily exenatide (N = 228) or
once daily glargine (N = 227) during the 26-week, non-
inferiority trial. The Vitality Scale of the Short Form 36, The Dia-
betes Symptom Checklist—Revised, The EuroQol instrument
(EQ-5D), The Treatment Flexibility Scale, and The Diabetes
Treatment Satisfaction Questionnaire (DTSQ) were administered
at baseline and endpoint. Change from baseline to endpoint was
compared within each treatment, and then between treatment
groups with analysis of covariance models, controlling for
country and baseline scores. RESULTS: At endpoint, exenatide
and glargine achieved similar HbA1c reductions. In each patient
reported outcome instrument, both treatment groups improved
from baseline to endpoint; however no statistically signiﬁcant
differences were observed between the treatment groups. Because
exenatide was associated with a higher incidence of nausea, the
impact of treatment satisfaction, as measured by the DTSQ, was
assessed for those exenatide patients who experienced nausea
during the trial (n = 126). These patients demonstrated improve-
ment from baseline to endpoint as well. CONCLUSIONS: Both
injectable medications signiﬁcantly improved the quality of life
when added to pre-existing oral therapy. Exenatide, injected
twice daily, was associated with an elevated incidence of nausea.
However, despite the addition of an injection requirement and
side effect of nausea, treatment satisfaction in exenitide group
was comparable to that of the glargine group.
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OBJECTIVE: In addition to weight reduction, there may be
other beneﬁts of obesity treatment including improved insulin
sensitivity. The purpose of this study was to characterise con-
comitant diabetes drug use and the related costs in diabetic
patients treated with orlistat in the ﬁrst six months of weight
management. METHODS: One hundred overweight diabetic
patients were enrolled in a structured weight management clinic
and treated with orlistat plus behavioural interventions. Among
other measures, weight, glucose control (HbA1c) and drug treat-
ments were recorded. Subjects were followed-up for a maximum
of 24 months at intervals of 6 months, with a maximum treat-
ment period of 24 months. RESULTS: The majority of subjects
(90%) had type-2 diabetes. They had a median age of 55 years
(IQR 47–63) and 55% were women. The mean BMI at baseline
was 39.51 with a mean HbA1c of 7.56%. The mean reduction
in weight at 6 months was 7.1kg (p < 0.001), with an average
absolute HbA1c improvement of 0.62% (p < 0.001). Of the 50
patients treated with insulin at baseline, three no longer required
insulin by the 6 month follow up. Of those treated with insulin,
the mean insulin dose was 130 iu (SD 135.4) at baseline and 
90 iu (SD 125.4) at 6 months (p < 0.001). Twenty patients (45%)
initially treated with oral hypoglycaemic agents alone reduced
their dose after 6 months. Despite marked improvement in
insulin sensitivity (baseline mean 1.24 iu/kg: 6 month mean 
0.90 iu/kg (p < 0.001)) there was no correlation with BMI
change. The average cost of diabetes treatment was £0.82 per
day at baseline and £0.59 at 6 months (D 28%; p < 0.001). CON-
CLUSIONS: Orlistat therapy, in conjunction with a structured
weight management programme, appears to reduce the need for
concomitant diabetes medication irrespective of weight loss. This
reduction is likely to translate into a large cost offset for orlistat
treatment.
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OBJECTIVES: To examine the effects of orlistat and rosiglita-
zone and assess the changes of cardiovascular risk factors in a
group of Chinese patients affected by the metabolic syndrome.
METHODS: In a prospective, 6-months randomized single-
blinded placebo-controlled study, 58 Chinese participants with
type-2 diabetes or impaired glucose tolerance, aged >18 years
with a BMI of 23kg/m2 or above were administered orally 
120mg orlistat three times daily, rosiglitazone 2mg twice daily
or placebo three times daily. Changes in clinical and metabolic
parameters of the metabolic syndrome were monitored, includ-
ing BMI, body fat, glycaemic control, lipid levels and drug tol-
erability. RESULTS: There were 20 individuals in the
rosiglitazone group and 19 individuals in both the orlistat and
placebo groups. There were statistically signiﬁcant differences
between the three groups in total cholesterol (p = 0.001), triglyc-
erides (p = 0.037), LDL-cholesterol (p = 0.001), BMI (p = 0.001),
hip (p = 0.002) and body fat (p = 0.006). The orlistat group
demonstrated improved lipid proﬁles from baseline, especially on
the reduction of total cholesterol (12% p = 0.0005) and LDL
(21%, p = 0.0002). This was accompanied by improvements in
the fasting insulin levels (p = 0.07) and Homeostatic Model
Assessment (HOMA) scores (p = 0.026). In comparison, the
rosiglitazone group exhibits maximum improvements in fasting
insulin (p = 0.004), 2hr-post OGTT insulin (p = 0.004) and
HOMA scores (p = 0.005). Although statistically insigniﬁcant,
there is a slight increase from baseline in the LDL levels (12%)
and body fat (3.7%). CONCLUSIONS: To prevent progression
to type-2 diabetes mellitus and its complications, early detection
and implementation of appropriate treatment strategies for the
metabolic syndrome is crucial. Both rosiglitazone and orlistat
appear to be promising in treating the metabolic syndrome.
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OBJECTIVES: To assess the clinical beneﬁts of add-on treatment
with Niaspan® (increases HDL-c) or ezetimibe (reduces LDL-c)
on coronary heart disease (CHD) in Type-2 diabetes patients
failing to reach target cholesterol levels on statin monotherapy.
METHODS: Two models were developed to project the clinical
beneﬁts of treatment over 10 years. The ﬁrst model (Monte Carlo
simulation) was used to evaluate the impact of simvastatin treat-
ment on lipid levels and identify patients with low HDL-c or high
LDL-c. Baseline cohort characteristics were taken from the 
diabetic sub-population of the 4S study. Patients with LDL-c 
<3mmol/L and HDL-c <1mmol/L received add-on Niaspan®.
Patients with LDL-c >3mmol/L received add-on ezetimibe. Each
add-on treatment was compared to statin monotherapy. Treat-
ment effects for both drugs were taken from several clinical trials
summarized in the European SPC. The second model (Markov
model) was used to evaluate the cumulative incidence of CHD
